PFE Research Update — September 18, 2026
Updated Thesis
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating margin of 25.1% show genuine pricing power in the product portfolio, but TTM net margin of only 6.8% and ROE of 4.9% reveal how much of that gross profit is consumed by research, litigation, impairments, and interest on $60.495 billion of long-term debt plus $2.699 billion of current debt. Revenue grew 2.6% year over year in the most recent quarter, while earnings fell 108.5% year over year in the most recent quarter, a swing driven by the prior-year COVID revenue base and by a $3.8 billion impairment tied to unfavorable Phase 3 sigvotatug vedotin results.
The investment grade as of this refresh is B — solid business quality. B-tier business, B-tier valuation with 12.0% upside to $30.94 fair value.
Key Metrics at a Glance
- Revenue growth: +2.6% year over year
- Net margin: 6.8%
- Fair value upside: +12.0% to our estimate of $31
Current price: $27.64
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Pfizer Inc. remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full PFE research →](/stocks/PFE)